Dr. Barry Jay Mark, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 21150 Biscayne Blvd, Suite 408, Aventura, FL 33180 Phone: 305-932-3252 Fax: 305-932-2798 |
Dr. Michelle Eisenfeld, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2925 Aventura Boulevard, Suite 308, Aventura, FL 33180 Phone: 305-932-5662 Fax: 305-932-1011 |
Luis Enrique Morera, ARNP Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 21150 Biscayne Blvd Ste 408, Aventura, FL 33180 Phone: 305-979-7195 |
Dr. Jaime Landman, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 21150 Biscayne Blvd, Suite 408, Aventura, FL 33180 Phone: 305-932-3252 Fax: 305-932-2798 |
Paul T Fass, MD Allergy & Immunology - Allergy Medicare: Not Enrolled in Medicare Practice Location: 2999 Ne 191st St, Suite 230, Aventura, FL 33180 Phone: 305-933-9953 |
Dr. Yoram Carmi Padeh, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2925 Aventura Blvd, Suite 308, Aventura, FL 33180 Phone: 305-932-5662 Fax: 305-932-1011 |
Mrs. Ellen Ann Sam, PA Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 21150 Biscayne Blvd, Suite 408, Aventura, FL 33180 Phone: 305-932-3252 Fax: 305-932-2798 |
News Archive
Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced that it has extended its contract with Nordion to supply molybdenum-99 (Mo-99) for use in its TechneLite (Technetium Tc 99m Generator) generators. Mo-99 is the parent isotope of technetium-99m (Tc-99m), the medical radioisotope most widely used in nuclear medicine diagnostic imaging tests.
Researchers from South Korea, Sweden, and the United States have collaborated on a project to restore neuron function to parts of the brain damaged by Huntington's disease (HD) by successfully transplanting HD-induced pluripotent stem cells into animal models.
Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.
Each of the 6.7 billion people on Earth has a signature body odor - the chemical counterpart to fingerprints - and scientists are tracking down those odiferous arches, loops, and whorls in the "human odorprint" for purposes ranging from disease diagnosis to crime prevention. That's the topic of an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.
Desperate times call for desperate measures and the latest idea to cut obesity rates especially in children is calling for 'car exclusion zones' around schools.
› Verified 6 days ago